Annovis Bio Secures $3.4 Million in Direct Offering to Advance Neurodegenerative Disease Therapies

Annovis Bio Inc. has secured $3.4 million through a registered direct offering of common stock, selling 1,670,732 shares at $2.05 per share. The transaction, which matched the closing price from October 24, was facilitated by H.C. Wainwright & Co. as the exclusive placement agent. Both Chairman Michael Hoffman and CEO Dr. Maria Maccecchini participated in the offering, demonstrating leadership commitment to the company's financial strategy. This capital infusion represents a strategic move for the clinical-stage biotechnology company as it advances its pipeline of therapies targeting Alzheimer's disease and Parkinson's disease, two conditions affecting millions of patients worldwide and representing significant unmet medical needs.

The company plans to allocate the proceeds toward working capital and general corporate purposes, directly supporting ongoing research and development efforts. The transaction is scheduled to close around October 28, 2025, providing Annovis Bio with additional resources to pursue its clinical objectives at a critical juncture in its development timeline. The funding comes as the company progresses its late-stage clinical programs, which employ a platform approach to drug development aimed at creating treatments that can modify disease progression rather than merely addressing symptoms. This distinction is particularly important in neurodegenerative disorders where symptom management has historically been the primary therapeutic approach.

The successful completion of this offering demonstrates continued investor confidence in Annovis Bio's approach to treating complex neurological disorders. As the company moves forward with its clinical development plans, this capital provides essential support for advancing potential treatments that could significantly impact patient care in neurodegenerative diseases. The company maintains transparency with the investment community through regular updates about its progress in developing innovative therapies. Additional information about Annovis Bio is available through the company's official website at https://www.annovisbio.com, where stakeholders can access comprehensive details about the company's research initiatives and clinical programs.

This financial development occurs within the broader context of increasing attention to neurodegenerative disease treatments, with Alzheimer's and Parkinson's representing substantial healthcare challenges globally. The company's focus on disease-modifying therapies rather than symptomatic treatments aligns with evolving scientific understanding of these conditions. The $3.4 million raised through this direct offering will enable continued progress in clinical trials and research activities, potentially accelerating the development timeline for therapies that address the underlying mechanisms of neurodegeneration. This funding round represents a calculated step in the company's financial strategy as it navigates the complex and capital-intensive process of bringing neurological treatments through clinical development and toward potential regulatory approval.